Showing results (1-10 of 73) with videos related to
Sort By:
Pageof 8
[Rinsho Ketsueki] the Japanese Journal of Clinical Hematology|June 3, 2026
[Treatment strategies for newly diagnosed multiple myeloma and the clinical significance of minimal residual disease negativity]Kazuhito SuzukiInternational Journal of Hematology|January 30, 2026
Recent advances in the pathophysiology and treatment of plasma cell dyscrasiasKazuhito SuzukiCancers|May 13, 2023
Treatment Strategy for Ultra-High-Risk Multiple Myelomas with Chromosomal Aberrations Considering Minimal Residual Disease Status and Bone Marrow MicroenvironmentKazuhito Suzuki, Shingo YanoLife (Basel, Switzerland)|November 25, 2023
IMiD-Free Interval and IMiDs Sequence: Which Strategy Is Better Suited for Lenalidomide-Refractory Myeloma?Kazuhito Suzuki, Shingo YanoLife (Basel, Switzerland)|March 28, 2024
Daratumumab Treatment for "Truly Frail" Elderly Myeloma PatientsYuichi Horigome, Kazuhito Suzuki, Takahiro SuzukiCancers|October 13, 2021
Treatment Strategy for Multiple Myeloma to Improve Immunological Environment and Maintain MRD NegativityKazuhito Suzuki, Kaichi Nishiwaki, Shingo YanoCancers|January 13, 2021
Treatment Strategies Considering Micro-Environment and Clonal Evolution in Multiple MyelomaKazuhito Suzuki, Kaichi Nishiwaki, Shingo YanoCureus|May 18, 2026
Surgical Treatment for an Infectious Aneurysm Caused by Perclose ProGlide®: A Case StudyYasutaka Imamura, Hiroshi Sasajima, Kazuho Kamishima, et al.Gan to Kagaku Ryoho. Cancer & Chemotherapy|March 25, 2010
[Successful induction of complete cytogenetic response with low-dose imatinib mesylate in an accelerated phase chronic myelogenous leukemia patient who developed severe bone marrow aplasia following standard-dose imatinib mesylate therapy]Tomonori Nakazato, Kazuhito Suzuki, Ai Mihara, et al.Internal Medicine (Tokyo, Japan)|August 2, 2019
Irreversible Vasculopathy Proceeds Rapidly in POEMS SyndromeKenichi Sakuta, Taiji Mukai, Kazuhito Suzuki, et al.Pageof 8